Welcome to our dedicated page for COVALON TECHS news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on COVALON TECHS stock.
Covalon Technologies Ltd. reports company developments across advanced medical technologies for vascular access, infection prevention, wound care, and surgical consumables. Recurring updates describe clinical education, healthcare-conference activity, and product use around contamination of intravenous connections, healthcare-associated infection risk, skin integrity, and patient-care workflows.
Covalon news also includes fiscal results, management discussion and analysis availability, shareholder meeting matters, director compensation through deferred share units, and amendments to governance documents and incentive plans. Product-specific coverage includes solutions such as CovaClear IV Cover dressings and VALGuard Vascular Access Line Guard.
Covalon Technologies announced strong Q2 fiscal 2024 results, with a 16% year-on-year revenue increase to $8.4 million. The company achieved an EBITDA of $1.7 million, adjusted EBITDA of $2.5 million, and an EPS of $0.06. US product segment revenue surged by 54%, contributing to the overall growth. Gross margins improved to 63%, the highest in recent company history. Operating expenses were reduced by 22% compared to the previous year, further boosting profitability. Additionally, the company noted a significant reduction in development and consulting services revenue to $0.06 million for the half-year period, down 97% from the prior year. A conference call to discuss these results is scheduled for May 29, 2024.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) will release its Q2 Fiscal 2024 financial results on May 29, 2024, before markets open. A conference call and webcast to discuss these results will be held the same day at 8:15am ET. Participants can join the call by dialing the provided phone numbers or access the live webcast via a link. The conference call will include a Q&A session where management will answer questions. A recording will be available on the Covalon website. Financial statements and MD&A can be accessed on SEDAR PLUS and Covalon’s website.
Covalon Technologies announced its participation in the Infusion Nurses Society Annual Meeting and Exhibition in Kansas City from May 18 to May 20, 2024. At booth #420, Covalon will showcase its advanced vascular access and infection control solutions, including VALGuard, IV Clear, and CovaClear IV. These products emphasize comfort, protection, and patient safety during infusion treatments. CEO Brent Ashton highlighted the company's dedication to combining efficacy and empathy in patient care.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.